title: Impact of diabetic polyneuropathy and cardiovascular autonomic neuropathy on the excretion of urinary 8-epi-PGF2alpha and its metabolites (2, 3-dinor and 2, 3-dinor-5, 6-dihydro).
abstract: The objective of this study was to establish if diabetes in the presence of polyneuropathy (PN) and/or cardiovascular autonomic neuropathy (CAN) is associated with alterations in the amounts of 8-epi-PGF2alpha (IP) and its metabolites including 2, 3-dinor-8-epi-PGF2alpha (dinor-IP) and 2, 3-dinor-5, 6 dihydro-8-epi-PGF2alpha (dinor-dihydro-IP) in urine. Mass spectrometric separation showed that excretion of IP was similar in the PN + /CAN- and PN+/CAN+ groups but higher than in the PN-/CAN- group (n = 103, 22 and 60, respectively; P < 0.05). By contrast, excretion of dinor-IP or dinor-dihydro-IP were similar in the PN-/CAN- and PN+/CAN- groups but higher than in PN+/CAN+ group. Correlations were obtained between IP and dinor-IP or dinor-dihydro-IP (r = 0.30; P < 0.001 and r = 0.31; P < 0.001, respectively). A significant association was also observed between dinor-IP and dinor-dihydro-IP (r = 0.48; P < 0.001). In conclusion, these biomarkers should prove useful in studies evaluating the impact of therapeutic drugs or antioxidant interventions aimed at delaying the onset of diabetic complications.
authors.affiliation: Department of Medicine, Royal Free and University College London School of Medicine, London, UK. jnouroozzadeh@yahoo.co.uk
authors.forename: Jaffar
authors.initials: J
authors.lastname: Nourooz-Zadeh
authors.forename: Christoph G
authors.initials: CG
authors.lastname: Sohr
authors.forename: Thierry
authors.initials: T
authors.lastname: Durand
authors.forename: Dan
authors.initials: D
authors.lastname: Ziegler
mesh_terms: D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000209:etiology / Q000652:urine*; D003920:Diabetes Mellitus / Q000652:urine*; D003922:Diabetes Mellitus, Type 1 / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000652:urine; D003929:Diabetic Neuropathies / Q000652:urine*; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism / Q000652:urine; D028441:F2-Isoprostanes / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D011115:Polyneuropathies / Q000209:etiology / Q000652:urine
chemical_list: C411579:2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha); C476546:2,3-dinor-8-iso-prostaglandin-F(2alpha); D028441:F2-Isoprostanes; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost